Cost Implications Of Tedizolid Introduction For The Treatment Of Complicated Skin And Soft Tissue Infections In A Russian Multi-Field Hospital

Abstract

treatment is expected to result in an additional 31,333 patients achieving SVR in 2017/18, with a net budget impact of ¥18.90 million in 2017 and-¥0.07 million in 2018. ConClusions: Introducing DUAL treatment for HCV in China is predicted to offer significant health-related benefit and a reduction in total lifetime cost, whilst having minimal impact (approximately 0.001% of total Chinese reimbursement expenditure) on total 2017/18 budget. PIN22 Budget ImPact Of INtrOducINg ceftazIdIme-avIBactam (caz-avI) fOr cOmPlIcated INtra-aBdOmINal INfectION (cIaI), cOmPlIcated urINary tract INfectIONs (cutI),

<p>Tedizolid phosphate for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy</p>

“…54–56 A first important point to be taken into account is the possibility of shorter treatment courses in comparison with other alternatives, including linezolid. In a simulated cohort of 100 inpatients, potential savings of €39,348 were projected by replacing linezolid with tedizolid for the treatment of suspected ABSSSI due to MRSA over a 1-year period 57,58. Notably, projections became cost-ineffective for simulated tedizolid treatment courses ≥9 days 57…”

“…In a simulated cohort of 100 inpatients, potential savings of €39,348 were projected by replacing linezolid with tedizolid for the treatment of suspected ABSSSI due to MRSA over a 1-year period 57,58. Notably, projections became cost-ineffective for simulated tedizolid treatment courses ≥9 days 57Figure 1Potential algorithm for considering tedizolid-based early switch (ES) to oral therapy and early discharge (ED) in patients with ABSSI. Note: Potential predictors of MRSA and factors indicating suitability for ES/ED have been extrapolated from the literature; data from references 54 and 55. Abbreviations: ABSSSI, acute bacterial skin and skin-structure infection; LRINEC, laboratory risk indicator for necrotizing fasciitis; MRSA, methicillin resistant Staphylococcus aureus ; WBCs, white blood cells.…”